Secnidazole Disease Interactions
There are 2 disease interactions with secnidazole.
Secnidazole (applies to secnidazole) Cockayne syndrome
Major Potential Hazard, Moderate plausibility.
Secnidazole is contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after start of metronidazole (another nitroimidazole drug structurally related to secnidazole) in patients with Cockayne syndrome.
Nitroimidazoles (applies to secnidazole) alcoholism
Moderate Potential Hazard, Moderate plausibility.
Nitroimidazoles (e.g., metronidazole, tinidazole, fexinidazole, secnidazole) may inhibit alcohol dehydrogenase and occasionally precipitate a disulfiram-like reaction in patients who consume alcohol while being treated. Symptoms may include abdominal cramps, nausea, vomiting, headache, flushing, rash, weakness, diarrhea, abdominal pain, dizziness, sweating, and hypotension. Patients should be instructed to avoid alcohol-containing products during nitroimidazole therapy and for at least 48 hours (fexinidazole, secnidazole) to 72 hours (metronidazole, tinidazole) after the last dose. Therapy with nitroimidazoles should be administered cautiously in patients who might be prone to acute alcohol intake. An alternative therapy may be appropriate.
Secnidazole drug interactions
There are 108 drug interactions with secnidazole.
More about secnidazole
- secnidazole consumer information
- Check interactions
- Compare alternatives
- Reviews (149)
- Side effects
- Dosage information
- During pregnancy
- Drug class: amebicides
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.